Bruker Corp BRKR
We take great care to ensure that the data presented and summarized in this overview for BRUKER CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BRKR
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD13MShares$743 Million0.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.7MShares$610 Million0.01% of portfolio
-
Black Rock Inc. New York, NY9.83MShares$560 Million0.01% of portfolio
-
Pallas Capital Advisors LLC Braintree, MA9.48MShares$541 Million27.58% of portfolio
-
Massachusetts Financial Services CO Boston, MA5.46MShares$311 Million0.12% of portfolio
-
State Street Corp Boston, MA3.63MShares$207 Million0.01% of portfolio
-
Alliancebernstein L.P. New York, NY3.55MShares$202 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY3.48MShares$198 Million3.83% of portfolio
-
London CO Of Virginia Richmond, VA2.35MShares$134 Million0.87% of portfolio
-
Geode Capital Management, LLC Boston, MA1.99MShares$114 Million0.01% of portfolio
Latest Institutional Activity in BRKR
Top Purchases
Top Sells
About BRKR
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Insider Transactions at BRKR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 02
2024
|
Richard A Packer |
SELL
Open market or private sale
|
Direct |
3,350
-3.98%
|
$190,950
$57.82 P/Share
|
Dec 02
2024
|
Richard A Packer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.61%
|
$190,000
$19.12 P/Share
|
Nov 22
2024
|
William A Linton |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.04%
|
$190,000
$19.12 P/Share
|
Nov 18
2024
|
Frank H Laukien PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+0.09%
|
$5,000,000
$50.67 P/Share
|
Aug 15
2024
|
Bob Rosenthal |
SELL
Open market or private sale
|
Direct |
4,684
-13.14%
|
$295,092
$63.14 P/Share
|
Aug 15
2024
|
Bob Rosenthal |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+15.39%
|
$275,000
$22.42 P/Share
|
Aug 11
2024
|
Gerald N Herman EXECUTIVE VICE PRESIDENT, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,067
-1.29%
|
$64,020
$60.42 P/Share
|
Aug 11
2024
|
Frank H Laukien PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,838
-0.01%
|
$290,280
$60.42 P/Share
|
Aug 11
2024
|
Mark Munch EXEC VP&PRES BRUKER NANO INC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,618
-1.46%
|
$97,080
$60.42 P/Share
|
Aug 10
2024
|
Gerald N Herman EXECUTIVE VICE PRESIDENT, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,471
-1.74%
|
$88,260
$60.42 P/Share
|
Aug 10
2024
|
Frank H Laukien PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,657
-0.01%
|
$279,420
$60.42 P/Share
|
Aug 10
2024
|
Mark Munch EXEC VP&PRES BRUKER NANO INC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,573
-1.4%
|
$94,380
$60.42 P/Share
|
Aug 09
2024
|
Juergen Srega PRESIDENT CALID |
BUY
Grant, award, or other acquisition
|
Direct |
16,936
+9.7%
|
-
|
Aug 09
2024
|
Falko Busse PRESIDENT, BIOSPIN GROUP |
BUY
Grant, award, or other acquisition
|
Direct |
6,030
+13.42%
|
-
|
Aug 09
2024
|
Gerald N Herman EXECUTIVE VICE PRESIDENT, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,106
+15.17%
|
-
|
Aug 09
2024
|
Frank H Laukien PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
28,307
+0.07%
|
-
|
Aug 09
2024
|
Mark Munch EXEC VP&PRES BRUKER NANO INC. |
BUY
Grant, award, or other acquisition
|
Direct |
15,022
+11.77%
|
-
|
Aug 09
2024
|
Burkhard Prause PRES. & CEO, BRUKER BEST |
BUY
Grant, award, or other acquisition
|
Direct |
2,795
+12.34%
|
-
|
Aug 06
2024
|
Frank H Laukien PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,174
-0.01%
|
$134,788
$62.16 P/Share
|
Aug 06
2024
|
Mark Munch EXEC VP&PRES BRUKER NANO INC. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,174
-2.18%
|
$134,788
$62.16 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 106K shares |
---|---|
Open market or private purchase | 100K shares |
Exercise of conversion of derivative security | 81.1K shares |
Payment of exercise price or tax liability | 30.5K shares |
---|---|
Open market or private sale | 66.5K shares |